Morphine and chronic cancer pain by Smit, B. J.
BRIEWE -
Therefo.re, when Mbewu writes about 'black South Africans'
it is not clear what he is referring to. However, despite the
terminology Dr Mbewu has misunderstood our message. We
do not say that Africans either alone or together with Indians
are immune to atherosclerosis. Our paper is in fact saying that
atherosclerotic disease is well established among African
patients (as well as in the other population groups). This
finding is supported by other studies from our institution.'·' We
also observed a difference in presentation and risk profile
between Indian and white patients on the one hand and
African patients on the other. However, for some reason that
we cannot understand we do not see African patients with
peripheral atherosclerosis presenting with ischaemic heart
disease as an anaesthetic risk factor.
We have an established protocol for the pre-operative
management of patients undergoing aortobifemoral bypass. A
comprehensive history is always taken, all patients undergo an
electrocardiogram, and those patients with a history of
ischaemic heart disease or an abnormal electrocardiogram
undergo a stress electrocardiogram, This protocol is well
established and cost effective. We do not use the Minnesota
classification and, furthermore, Seedat et a/S demonstrated that
this classification was unreliable for eliciting ischaemic heart
disease in Africans.
In our study' there was no history of ischaemic heart disease
and no evidence of this condition on pre-operative
electrocardiograms. None of our patients from all groups had
morbidity related to ischaemic heart disease. Mbewu attributes
our findings to linlited access of 'black South Africans' to
electrocardiography. This does not apply to our study because
all patients were submitted to the same protocol in the same
vascular unit by the same surgical team and all the patients
had access to electrocardiography as part of pre-operative
management strategy.
A point must be made, however, that we were looking at
anaesthetic risk factors for this type of surgery - we were not
looking for subtle signs and symptoms of ischaemic heart
disease.
We do not dispute the findings of Mayosi et al. (as quoted by
Mbewu l ) who noted high prevalences of risk factors such as
smoking, diabetes and hypertension in black South Africans
admitted to a coronary care unit. Again, it is not clear from the
correspondence by Mbewu whether that study included
Indians and Africans or whether it looked at Africans only. The
presence of risk factors such as smoking, diabetes and
CToPJII hypertension was also observed among African patients in our
l&WII shldy, but despite that there was no history of ischaemic heart
disease or abnormal electrocardiograms in African patients in
our study. In the study by Seedat et aU the prevalence of
ischaemic heart disease in Africans was 2.4%. In that study
'black' denoted 'African'.
In conclusion, we agree with Dr Mbewu that further srudies
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of ischaemic heart disease need to be done on black South
Africans, with special emphasis on African patients, in order to
look at the incidence of ischaemic heart disease.
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MORPHINE AND CHRONIC CANCER PAIN
To the Editor: Cancer pain can be broken down into the
following categories: (i),pain caused by the cancer process
itself, i.e. bony invasion or nerve compression or infiltration
that is likely to present with the features of acute pain; (ii) pain
arising from the treatment for the cancer process and likely to
present as chronic pain - this might include pain resulting
from radical surgery, chemotherapy or radiation therapy; and
(hi) bedsores, chronic infection or constipation, which may
become part of the pain syndrome.
Chronic pain is not easy to assess, but will affect attitude and
lifestyle, will need long-term medication, and will involve
many individuals besides the patient. Furthermore,
expectations of the results of medication need to be realistic.
The International Association for the Study of Pain (lASP)
created the first multi-axial system based on the region of the
body involved in chronic pain, the organ system affected, the
temporal characteristics and pattern of the pain, its duration
and intensity and the source of pain, and a taxonOlnic
classification has been made. Thoracic pain, for example, is
'300' (region) and respiratory system pain is '20'.
All the above have been efforts to make pain relief as
'logical' as possible!
The management of pain is typically pyramidal: mild pain is
treated with non-opioid analgesics (e.g. paracetamol or non-
steroidal anti-inflammatory agents), moderate pain with opioid
analgesics of weak to moderate strength (e.g. codeine), and
severe pain is treated with strong opioid analgesics, e.g.
morphine.
Morphine is the most frequently used of the strong opioid
analgesics. For chronic pain management oral administration is
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favoured, either as an elixir or an immediate-release or slow-
release tablet. Usually the elixir is used to titrate the dose
required for effective analgesia. Dosage intervals of 2 - 6 ;,ours
are needed (usually 4 hours) Once the correct (effective) dosage
rate is obtained, the patient can be switched to the equivalent
in controlled release form, if desired.
An article in Time magazine (28 April 1997, pp. 56 - 57)
describes the 'mailbox effect' ef morphine (morphine blocks the
pain signals to the brain in the spinal cord). This article is well
worth reading, as it makes a strong case for the chronic use of
morphine in patients with chronic severe pain. It also warns
about the prejudice of doctors who are not really familiar with
the problems of chronic pain with regard to the prescription of
morphine. A photo summarises the essential point: 'a patient
finds relief - not addiction'.
Disadvantages of opioids are constipation (sometimes),
nausea and vomiting, sedation, respiratory depression,
tolerance and dependence. In my experience the latter is of
little trouble in the terminally ill patient, and morphine does
not really seem to be addictive when it is direly needed to keep
pain under control.
Respiratory depression following opioid administration at
the appropriate dose level is minimal in those patients who
have pain.
Tricyclic antidepressants may further help and sometime
anticonvulsants like carbamazepine may be of further help in
the patient with pain, and steroids can relieve nerve and bone
pain.
The bottom line, however, is that we oncologists use litres
and litres of the elixir, and we are extremely frustrated by the
'fear' of day clinic doctors, general practitioners, etc. to
prescribe adequate quantities to terminal cancer patients with
pain.
The usual elixir is 20 mg per 5 ml, and the lowest effective
dose is usually 2.5 ml of this -l-hourly, which mean a do e of
15 ml daily, or 500 ml monthly. This could easily reach levels 2 -
3 times higher than this! So to issue 50 ml or 100 ml is totally
useless.
I wish this message could for once be understood!
(Don't forget the laxative with the morphine!)
BJSmit
Radiatioll OllcoJogy
Tlfgerberg Hospital
Tygerberg, WCape
flatLining?
